Latest Anemia News
In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
New study finds no difference in all-cause and cause-specific mortality between iron sucrose and sodium ferric gluconate complex.
Use of ESAs declined while use of blood transfusions increased between 2008 and 2012.
The surface chemistry of the polymer reacts to the pH level of blood as it travels through the body.
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
US patients receive higher intravenous iron and ESA doses during the first year of hemodialysis compared with those in Europe.
Low vitamin D status was associated with a 2-fold higher risk for anemia.
Results were homogeneous, with differences in absolute mortality consistently less than 1% among the most extreme exposure categories.
Pending future research, patients should avoid taking more than 120 mg per day.
SHPT patients who received 6 months of cinacalcet treatment had a 10% increase in the odds of reaching target hemoglobin levels.
Study finds no increased risk of major adverse cardiovascular events and death.
Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.
Management strategy also is associated with reduced mortality risk, but not achievement of hemoglobin targets.
End-stage renal disease is 32% more likely to develop in patients with C-reactive protein levels of 6.9 mg/L or higher vs 3.0 mg/L or lower.
Other risk factors include reduced muscle mass and lower levels of physical activity.